Literature DB >> 28689240

suPAR and chronic kidney disease-a podocyte story.

Martin Zeier1, Jochen Reiser2.   

Abstract

The soluble urokinase-type plasminogen activator receptor (suPAR) is a circulating signaling molecule derived from immature myeloid cells. Elevated levels of suPAR have been linked to the pathogenesis of the kidney disease focal and segmental glomerulosclerosis. Here, suPAR acts on podocytes by activating αvβ3 integrins. Large observational studies showed that suPAR also predicts chronic kidney disease incidence and progression by predating the disease by several years prior to any other known marker of renal dysfunction. suPAR is rapidly developing into a prime target for pharmacotherapy as its neutralization is forecasted to be feasible and safe.

Entities:  

Keywords:  CKD; FSGS; Integrin; Podocyte; suPAR

Mesh：

Substances：

Year:  2017        PMID： 28689240     DOI： 10.1007/s00424-017-2026-7

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN： 0031-6768            Impact factor:   3.657


  23 in total

1.  Management of severe recurrent focal segmental glomerulosclerosis through circulating soluble urokinase receptor modification.

Authors:  Christian Morath; Changli Wei; Stephan Macher-Goeppinger; Vedat Schwenger; Martin Zeier; Jochen Reiser
Journal:  Am J Ther       Date:  2013 Mar-Apr       Impact factor: 2.688

Review 2.  A potential role for mechanical forces in the detachment of podocytes and the progression of CKD.

Authors:  Wilhelm Kriz; Kevin V Lemley
Journal:  J Am Soc Nephrol       Date:  2014-07-24       Impact factor: 10.121

3.  Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte β3-integrin Activation.

Authors:  Oliver Staeck; Torsten Slowinski; Ina Lieker; Kaiyin Wu; Birgit Rudolph; Danilo Schmidt; Susanne Brakemeier; Hans-Hellmut Neumayer; Changli Wei; Jochen Reiser; Klemens Budde; Fabian Halleck; Dmytro Khadzhynov
Journal:  Transplantation       Date:  2015-12       Impact factor: 4.939

4.  Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study.

Authors:  J C Peterson; S Adler; J M Burkart; T Greene; L A Hebert; L G Hunsicker; A J King; S Klahr; S G Massry; J L Seifter
Journal:  Ann Intern Med       Date:  1995-11-15       Impact factor: 25.391

5.  Soluble Urokinase Receptor and Chronic Kidney Disease.

Authors:  Salim S Hayek; Sanja Sever; Yi-An Ko; Howard Trachtman; Mosaab Awad; Shikha Wadhwani; Mehmet M Altintas; Changli Wei; Anna L Hotton; Audrey L French; Laurence S Sperling; Stamatios Lerakis; Arshed A Quyyumi; Jochen Reiser
Journal:  N Engl J Med       Date:  2015-11-05       Impact factor: 91.245

6.  Decreased glomerular filtration as the primary factor of elevated circulating suPAR levels in focal segmental glomerulosclerosis.

Authors:  Yutaka Harita; Kiyonobu Ishizuka; Atsushi Tanego; Noriko Sugawara; Hiroko Chikamoto; Yuko Akioka; Haruko Tsurumi; Kenichiro Miura; Yoshimitsu Gotoh; Makoto Tsujita; Takayuki Yamamoto; Keiji Horike; Asami Takeda; Akira Oka; Takashi Igarashi; Motoshi Hattori
Journal:  Pediatr Nephrol       Date:  2014-04-06       Impact factor: 3.714

7.  A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease.

Authors:  Joann M Spinale; Laura H Mariani; Shiv Kapoor; Jidong Zhang; Robert Weyant; Peter X Song; Hetty N Wong; Jonathan P Troost; Crystal A Gadegbeku; Debbie S Gipson; Matthias Kretzler; Deepak Nihalani; Lawrence B Holzman
Journal:  Kidney Int       Date:  2014-10-29       Impact factor: 10.612

8.  Soluble urokinase receptor (suPAR) predicts microalbuminuria in patients at risk for type 2 diabetes mellitus.

Authors:  Martina Guthoff; Robert Wagner; Elko Randrianarisoa; Erifili Hatziagelaki; Andreas Peter; Hans-Ulrich Häring; Andreas Fritsche; Nils Heyne
Journal:  Sci Rep       Date:  2017-01-16       Impact factor: 4.379

9.  Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease.

Authors:  Eunsil Hahm; Changli Wei; Isabel Fernandez; Jing Li; Nicholas J Tardi; Melissa Tracy; Shikha Wadhwani; Yanxia Cao; Vasil Peev; Andrew Zloza; Jevgenijs Lusciks; Salim S Hayek; Christopher O'Connor; Markus Bitzer; Vineet Gupta; Sanja Sever; David B Sykes; David T Scadden; Jochen Reiser
Journal:  Nat Med       Date:  2016-12-12       Impact factor: 53.440

10.  Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes.

Authors:  Massimo Alfano; Paola Cinque; Guido Giusti; Silvia Proietti; Manuela Nebuloni; Silvio Danese; Silvia D'Alessio; Marco Genua; Federica Portale; Manuela Lo Porto; Pravin C Singhal; Maria Pia Rastaldi; Moin A Saleem; Domenico Mavilio; Joanna Mikulak
Journal:  Sci Rep       Date:  2015-09-18       Impact factor: 4.379
View more
  18 in total

1.  Plasma Soluble Urokinase Plasminogen Activator Receptor (suPAR) and CKD Progression in Children.

Authors:  Darcy K Weidemann; Alison G Abraham; Jennifer L Roem; Susan L Furth; Bradley A Warady
Journal:  Am J Kidney Dis       Date:  2020-01-24       Impact factor: 8.860

2.  Mechanisms underlying modulation of podocyte TRPC6 channels by suPAR: Role of NADPH oxidases and Src family tyrosine kinases.

Authors:  Eun Young Kim; Naghmeh Hassanzadeh Khayyat; Stuart E Dryer
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-08-08       Impact factor: 5.187

3.  Ultrastructural Characterization of the Glomerulopathy in Alport Mice by Helium Ion Scanning Microscopy (HIM).

Authors:  Kenji Tsuji; Hani Suleiman; Jeffrey H Miner; James M Daley; Diane E Capen; Teodor G Păunescu; Hua A Jenny Lu
Journal:  Sci Rep       Date:  2017-09-15       Impact factor: 4.379

4.  Soluble urokinase plasminogen activation receptor and long-term outcomes in persons undergoing coronary angiography.

Authors:  Claudia Sommerer; Martin Zeier; Christian Morath; Jochen Reiser; Hubert Scharnagl; Tatjana Stojakovic; Graciela E Delgado; Winfried März; Marcus E Kleber
Journal:  Sci Rep       Date:  2019-01-24       Impact factor: 4.379

5.  Inhibiting the urokinase-type plasminogen activator receptor system recovers STZ-induced diabetic nephropathy.

Authors:  Massimo Dal Monte; Maurizio Cammalleri; Valeria Pecci; Monica Carmosino; Giuseppe Procino; Alessandro Pini; Mario De Rosa; Vincenzo Pavone; Maria Svelto; Paola Bagnoli
Journal:  J Cell Mol Med       Date:  2018-11-13       Impact factor: 5.310

6.  Gut microbiome-derived phenyl sulfate contributes to albuminuria in diabetic kidney disease.

Authors:  Koichi Kikuchi; Daisuke Saigusa; Yoshitomi Kanemitsu; Yotaro Matsumoto; Paxton Thanai; Naoto Suzuki; Koki Mise; Hiroaki Yamaguchi; Tomohiro Nakamura; Kei Asaji; Chikahisa Mukawa; Hiroki Tsukamoto; Toshihiro Sato; Yoshitsugu Oikawa; Tomoyuki Iwasaki; Yuji Oe; Tomoya Tsukimi; Noriko N Fukuda; Hsin-Jung Ho; Fumika Nanto-Hara; Jiro Ogura; Ritsumi Saito; Shizuko Nagao; Yusuke Ohsaki; Satoshi Shimada; Takehiro Suzuki; Takafumi Toyohara; Eikan Mishima; Hisato Shima; Yasutoshi Akiyama; Yukako Akiyama; Mariko Ichijo; Tetsuro Matsuhashi; Akihiro Matsuo; Yoshiaki Ogata; Ching-Chin Yang; Chitose Suzuki; Matthew C Breeggemann; Jurgen Heymann; Miho Shimizu; Susumu Ogawa; Nobuyuki Takahashi; Takashi Suzuki; Yuji Owada; Shigeo Kure; Nariyasu Mano; Tomoyoshi Soga; Takashi Wada; Jeffrey B Kopp; Shinji Fukuda; Atsushi Hozawa; Masayuki Yamamoto; Sadayoshi Ito; Jun Wada; Yoshihisa Tomioka; Takaaki Abe
Journal:  Nat Commun       Date:  2019-04-23       Impact factor: 14.919

7.  Increased Serum Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels in FSGS: A Meta-Analysis.

Authors:  Jiwon M Lee; Jae Won Yang; Andreas Kronbichler; Michael Eisenhut; Gaeun Kim; Keum Hwa Lee; Jae Il Shin
Journal:  J Immunol Res       Date:  2019-04-04       Impact factor: 4.818

8.  Diagnostic and Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) in Focal Segmental Glomerulosclerosis and Impact of Detection Method.

Authors:  Wolfgang Winnicki; Gere Sunder-Plassmann; Gürkan Sengölge; Ammon Handisurya; Harald Herkner; Christoph Kornauth; Bernhard Bielesz; Ludwig Wagner; Željko Kikić; Sahra Pajenda; Thomas Reiter; Benjamin Schairer; Alice Schmidt
Journal:  Sci Rep       Date:  2019-09-24       Impact factor: 4.379

Review 9.  Nanobodies: new avenue to treat kidney disease.

Authors:  Nicola Wanner; Thomas Eden; Nastassia Liaukouskaya; Friedrich Koch-Nolte
Journal:  Cell Tissue Res       Date:  2021-06-16       Impact factor: 4.051

10.  Association of Multiple Plasma Biomarker Concentrations with Progression of Prevalent Diabetic Kidney Disease: Findings from the Chronic Renal Insufficiency Cohort (CRIC) Study.

Authors:  Sarah J Schrauben; Haochang Shou; Xiaoming Zhang; Amanda Hyre Anderson; Joseph V Bonventre; Jing Chen; Steven Coca; Susan L Furth; Jason H Greenberg; Orlando M Gutierrez; Joachim H Ix; James P Lash; Chirag R Parikh; Casey M Rebholz; Venkata Sabbisetti; Mark J Sarnak; Michael G Shlipak; Sushrut S Waikar; Paul L Kimmel; Ramachandran S Vasan; Harold I Feldman; Jeffrey R Schelling
Journal:  J Am Soc Nephrol       Date:  2020-10-29       Impact factor: 14.978
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.